122 related articles for article (PubMed ID: 35675759)
21. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.
Amato E; Molin MD; Mafficini A; Yu J; Malleo G; Rusev B; Fassan M; Antonello D; Sadakari Y; Castelli P; Zamboni G; Maitra A; Salvia R; Hruban RH; Bassi C; Capelli P; Lawlor RT; Goggins M; Scarpa A
J Pathol; 2014 Jul; 233(3):217-27. PubMed ID: 24604757
[TBL] [Abstract][Full Text] [Related]
22. Pancreatobiliary-type intraductal papillary mucinous neoplasm of the pancreas may have 2 subtypes with distinct clinicopathologic and genetic features.
Shimizu T; Akita M; Sofue K; Toyama H; Itoh T; Fukumoto T; Zen Y
Hum Pathol; 2019 Sep; 91():26-35. PubMed ID: 31175918
[TBL] [Abstract][Full Text] [Related]
23. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
[TBL] [Abstract][Full Text] [Related]
24. Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach.
Weaver DT; Lietz AP; Mercaldo SF; Peters MLB; Hur C; Kong CY; Wolpin BM; Megibow AJ; Berland LL; Knudsen AB; Pandharipande PV
AJR Am J Roentgenol; 2019 Mar; 212(3):596-601. PubMed ID: 30620679
[TBL] [Abstract][Full Text] [Related]
25. Multiphase computed tomography radiomics of pancreatic intraductal papillary mucinous neoplasms to predict malignancy.
Polk SL; Choi JW; McGettigan MJ; Rose T; Ahmed A; Kim J; Jiang K; Balagurunathan Y; Qi J; Farah PT; Rathi A; Permuth JB; Jeong D
World J Gastroenterol; 2020 Jun; 26(24):3458-3471. PubMed ID: 32655269
[TBL] [Abstract][Full Text] [Related]
26. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic CT density is an optimal imaging biomarker for earlier detection of malignancy in the pancreas with intraductal papillary mucinous neoplasm.
Yamada D; Kobayashi S; Takahashi H; Yoshioka T; Iwagami Y; Tomimaru Y; Shigekawa M; Akita H; Noda T; Asaoka T; Gotoh K; Tanemura M; Doki Y; Eguchi H
Pancreatology; 2022 May; 22(4):488-496. PubMed ID: 35396159
[TBL] [Abstract][Full Text] [Related]
28. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
[TBL] [Abstract][Full Text] [Related]
29. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
[TBL] [Abstract][Full Text] [Related]
30. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.
Kamata K; Kitano M; Kudo M; Sakamoto H; Kadosaka K; Miyata T; Imai H; Maekawa K; Chikugo T; Kumano M; Hyodo T; Murakami T; Chiba Y; Takeyama Y
Endoscopy; 2014 Jan; 46(1):22-9. PubMed ID: 24218310
[TBL] [Abstract][Full Text] [Related]
31. Management and outcomes of intraductal papillary mucinous neoplasms.
Hipp J; Mohamed S; Pott J; Sick O; Makowiec F; Hopt UT; Fichtner-Feigl S; Wittel UA
BJS Open; 2019 Aug; 3(4):490-499. PubMed ID: 31388641
[TBL] [Abstract][Full Text] [Related]
32. Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: Criteria and clinical implications of accurate diagnosis.
Reid MD; Stallworth CR; Lewis MM; Akkas G; Memis B; Basturk O; Adsay V
Cancer Cytopathol; 2016 Feb; 124(2):122-34. PubMed ID: 26415076
[TBL] [Abstract][Full Text] [Related]
33. Higher Growth Rate of Branch Duct Intraductal Papillary Mucinous Neoplasms Associates With Worrisome Features.
Kolb JM; Argiriadi P; Lee K; Liu X; Bagiella E; Gupta S; Lucas AL; Kim MK; Kumta NA; Nagula S; Sarpel U; DiMaio CJ
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1481-1487. PubMed ID: 29535058
[TBL] [Abstract][Full Text] [Related]
34. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
[TBL] [Abstract][Full Text] [Related]
35. Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms.
Felix K; Honda K; Nagashima K; Kashiro A; Takeuchi K; Kobayashi T; Hinterkopf S; Gaida MM; Dang H; Brindl N; Kaiser J; Büchler MW; Strobel O
Int J Cancer; 2022 Mar; 150(5):881-894. PubMed ID: 34778955
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of conservative surgery for pancreatic IPMNs.
Palmeri M; Di Franco G; Bianchini M; Guadagni S; Gianardi D; Furbetta N; Caprili G; Fatucchi LM; Sbrana A; Funel N; Pollina LE; Di Candio G; Morelli L
Surg Oncol; 2021 Sep; 38():101582. PubMed ID: 33892432
[TBL] [Abstract][Full Text] [Related]
37. Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms.
Mandai K; Uno K; Nakase K; Kawamura T; Yasuda K
J Med Ultrason (2001); 2019 Oct; 46(4):435-439. PubMed ID: 31069577
[TBL] [Abstract][Full Text] [Related]
38. Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms.
Crippa S; Pergolini I; Rubini C; Castelli P; Partelli S; Zardini C; Marchesini G; Zamboni G; Falconi M
Surgery; 2016 Apr; 159(4):1041-9. PubMed ID: 26704784
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas.
Mito K; Saito M; Morita K; Maetani I; Sata N; Mieno M; Fukushima N
Pancreatology; 2018 Jun; 18(4):407-412. PubMed ID: 29650332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
